Immunohistochemical markers for prognosis of oligodendroglial neoplasms

Journal of Neuro-Oncology

Volumn 58, Issue 3, 2002, Pages 237-253

  Korshunov, Andrey ^a   Golanov, Andrey ^a   Sycheva, Regina ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

Grading; Immunohistochemistry; Ki S1; Oligodendroglioma; p27; Prognosis

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; NUCLEAR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; BIOCHEMICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; PROTEIN MDM2; PROTEIN P14; PROTEIN P18; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; ARTICLE; BRAIN TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; OLIGODENDROGLIOMA; PATHOLOGY; PROGNOSIS; SURVIVAL; ANTIGEN EXPRESSION; BIOPSY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN CELL; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; MODEL; MULTIVARIATE ANALYSIS; OLIGODENDROGLIA; OUTCOMES RESEARCH; PREDICTION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR REGRESSION;

ADULT; ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OLIGODENDROGLIOMA; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; HUMAN; MIDDLE AGE;

EID: 0036020498     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016270101321     Document Type: Article

References (109)

1. Tumors of central neuroepithelial origin
2. Oligodendroglial neoplasms: Current concepts, misconceptions, and folklore
3. Oligodendrogliomas in the CT/MR-Era
4. Treatment of oligodendroglioma: An update
5. Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and precursor cells
6. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors
7. OLIG2 as a specific marker of oligodendroglial tumour cells
8. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas
9. Clinicopathologic correlations in the oligodendroglioma
10. Cerebral oligodendroglioma: Prognostic factors and life history
11. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
12. Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases
13. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria
14. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases
15. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
16. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
17. Oligodendroglioma: A comparison of two grading systems
18. Oligodendroglioma: The Rotterdam-Dijkzigt experience
19. A clinicopathological study of 323 patients with oligodendrogliomas
20. Oligodendroglioma. Histologic evaluation and prognosis
21. Prognostic factors in oligodendrogliomas
22. The prognostic role of vessel productive changes and vessel density in oligodendroglioma
23. Oligodendrogliomas: The Mayo Clinic experience
24. Grading of oligodendrogliomas
25. Evaluation of malignant features in oligodendroglial tumors
26. Prognostic significance of the endothelial surface in low-grade resected oligodendroglioma
27. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis
28. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas
29. Immunohistochemical investigation of p53 and EGFR expression of oligodendrogliomas
30. p27/kip1 expression in oligodendrogliomas and its possible prognostic role
31. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas
32. Prognostic relevance of TP53 mutation, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas
33. CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue
34. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
35. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value
36. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases
37. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas
38. Immunohistochemical analysis of p18INK4C and p14ARF protein expression in 117 oligodendrogliomas: Correlation with tumor grade and clinical outcome
39. Expression of p53 in oligodendrogliomas
40. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
41. Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor
42. High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas
43. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas
44. Cell cycle regulators (p21, p53, pRB) in oligodendrocytic tumors: A study by novel tumor microarray technique
45. p53 immunoreactivity in oligodendrogliomas
46. Clinicopathological study of forty-four histologically pure supratentorial oligodendrogliomas
47. Evaluation of cell proliferation, epidermal growth factor receptor and bcl-2 immunoexpression as prognostic factors for patients with World Health organization grade 2 oligodendrogliomas
48. Vascular endothelial growth factor expression in oligodendrogliomas: A correlative study with Saint-Anne malignancy grade, growth fraction and patient survival
49. Prognostic significance of clinical and angiogenesis-related factors in low-grade oligodendroglioma
50. Proliferation and cell death in oligodendrogliomas
51. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis
52. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
53. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
54. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections
55. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
56. Molecular subtypes of anaplastic oligodendroglioma
57. Glioma classification: A molecular reappraisal
58. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay
59. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis
60. Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas
61. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival
62. Immunohistochemical staining of DNA topoisomerase II a in human gliomas
63. Gene expression profiling with oligonucleotide microassays distinguishes World Health Organization grade of oligodendrogliomas
64. Integration of pRB and p53 cell cycle control pathways
65. Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors
66. Molecular genetic analysis of non-astrocytic gliomas
67. Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas
68. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification
69. Prognostic factors in malignant glioma: Influence of the overexpression of oncogene and tumor-suppressor gene products on survival
70. Cip/Kip cell-cycle inhibitors: A neuro-oncological perspective
71. Analysis of cyclin dependent kinase inhibitors in malignant astrocytomas
72. Increased levels of p21 (WAF1/Cip1) in human brain tumors
73. Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis
74. Prognostic value of the expression of tumor suppressor genes p53, p21, p16, and pRb, and Ki-67 labelling in high-grade astrocytomas treated with radiotherapy
75. Expression of retinoblastoma gene product and p21 (WAF1/Cip1) protein in gliomas: Correlation with proliferation markers, p53 expression and survival
76. Analysis of the p21 gene in gliomas
77. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression
78. p27Kip1 expression by contact inhibition as a prognostic index of human glioma
79. Expression of cell cycle regulator p27kip1 is correlated with survival of patients with astrocytoma
80. Anomalous p27kip1 expression in a subset of malignant gliomas
81. p27/kip1 expression in human astrocytic gliomas
82. High cyclin E/low p27kip1 expression is associated with poor prognosis in astrocytomas
83. p27/kip1 expression in oligodendrogliomas and its possible prognostic role
84. Accumulation of the cyclin-dependent kinase inhibitor p27/kip1 and the timing in oligodendrocyte differentiation
85. Ectopic expression of p27Kip1 in oligodendrocyte progenitor cells results in cell-cycle growth arrest
86. High level expression of p27Kip1 and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27Kip1 and degree of malignancy in human breast and colorectal cancers
87. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin dependent kinases CDK4 and CDK6
88. Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors
89. p18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia
90. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors
91. Homozygous deletion of the CDKN2C/p18INK4C gene on the short arm of the chromosome 1 in anaplastic oligodendrogliomas
92. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development
93. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development
94. The INK4A/ARF locus: Role in cell cycle control and apoptosis and implication for glioma growth
95. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities
96. p14ARF deletion and methylation in genetic pathways to glioblastomas
97. Promoter hypermethylation and homozygous deletion of p14ARF and p16INK4a genes in oligodendrogliomas
98. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus
99. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade gliomas
100. Expression of vascular endothelial growth factor and its receptors in anaplastic progression of astrocytoma, oligodendroglioma and ependymoma
101. Vascular endothelial growth factor (VEGF) in astrocytic gliomas - A prognostic factor?
102. Expression and distribution of vascular endothelial growth factor protein in human brain tumors
103. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas
104. Nitric oxide synthase expression of oligodendrogliomas
105. PCV for oligodendroglial tumors: In search of prognostic factor for response and survival
106. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms
107. Multidrug sensitivity of phenotype of human lung cancer cells associated with topoisomerase II expression
108. Correlation between DNA topoisomerase II alpha expression and sensitivity to etoposide in human glioma cell lines